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Abstract
Background: In 2001 the National Cholesterol Education Program (NCEP) provided a categorical
definition for metabolic syndrome (c-MetS). We studied the extent to which two ethnic groups,
Blacks and Whites were affected by c-MetS. The groups were members of the Hypertension
Genetic Epidemiology Network (HyperGEN), a part of the Family Blood Pressure Program,
supported by the NHLBI. Although the c-MetS definition is of special interest in particular to the
clinicians, the quantitative latent traits of the metabolic syndrome (MetS) are also important in
order to gain further understanding of its etiology. In this study, quantitative evaluation of the MetS
latent traits (q-MetS) was based on the statistical multivariate method factor analysis (FA).
Results: The prevalence of the c-MetS was 34% in Blacks and 39% in Whites. c-MetS showed
predominance of obesity, hypertension, and dyslipidemia. Three and four factor domains were
identified through FA, classified as "Obesity," "Blood pressure," "Lipids," and "Central obesity."
They explained approximately 60% of the variance in the 11 original variables. Two factors classified
as "Obesity" and "Central Obesity" overlapped when FA was performed without rotation. All four
factors in FA with Varimax rotation were consistent between Blacks and Whites, between genders
and also after excluding type 2 diabetes (T2D) participants. Fasting insulin (INS) associated mainly
with obesity and lipids factors.
Conclusions: MetS in the HyperGEN study has a compound phenotype with separate domains
for obesity, blood pressure, and lipids. Obesity and its relationship to lipids and insulin is clearly the
dominant factor in MetS. Linkage analysis on factor scores for components of MetS, in familial
studies such as HyperGEN, can assist in understanding the genetic pathways for MetS and their
interactions with the environment, as a first step in identifying the underlying pathophysiological
causes of this syndrome.
Background
Metabolic and physiologic disorders for cardiovascular
disease (CVD) and type 2 diabetes (T2D), including
abdominal obesity, insulin resistance, hyperglycemia,
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is frequently identified as the "metabolic syndrome"
(MetS). Reaven [1] related MetS to the presence of resist-
ance to insulin-mediated glucose disposal, glucose intol-
erance, hyperinsulinemia, increased triglycerides,
decreased high-density lipoprotein cholesterol, and
hypertension. Later, the definition of MetS was extended
to include obesity, inflammation, microalbuminuria, and
abnormalities of fibrinolysis and of coagulation [2-4].
Clearly, insulin resistance is not considered equivalent to
MetS [5,6]. Grundy et al. [7], at a recent National Heart,
Lung, and Blood Institute (NHLBI) /American Heart Asso-
ciation (AHA) National Conference, concluded that
abdominal obesity is strongly associated with MetS. Son-
nenberg et al. [8] have hypothesized that increased adi-
pose tissue mass contributes to the development of MetS
by triggering an increase in proinflammatory adipokines,
especially the tumor necrosis factor-α, which may play a
role in the pathogenesis of dyslipidemia, insulin resist-
ance, hypertension, endothelial dysfunction, and athero-
genesis. Although several studies have targeted MetS, its
genetic determination and its pathophysiology remain
unclear [9].
Different definitions and multivariate statistical
approaches have been applied to characterize the increas-
ing high-risk MetS premorbid state. Recently, special
attention has received the categorical definition of meta-
bolic syndrome (c-MetS) of the National Cholesterol Edu-
cation Program Adult Treatment Panel III (NCEP) [2]. The
NCEP definition (see Material and Methods) has espe-
cially two components, its usefulness in the clinical diag-
nosis of MetS and its association with recommendations
for its therapeutic treatment. Based on the NCEP c-MetS
definition, it is reported that 20 to 25 percent of the U.S.
adult population has MetS. This represents a high preva-
lence of the syndrome in the general population [10,11].
In addition, employing the multivariate statistical method
factor analysis (FA) different studies in different sampled
populations have documented the underlying latent traits
of MetS [4,12-17]. Meigs [3] has reported that FA in differ-
ent studies has yielded on average 2 to 4 latent traits (fac-
tors) of MetS. Different studies have found different
numbers of latent factors, depending on the type and
number of the original risk factors analyzed, sampled
population(s), methods utilized, including the statistical
rotation method, and decisions about how many factors
appeared statistically meaningful.
The objective of this study was to exemplify important fac-
ets of the MetS in the HyperGEN study. Two MetS aspects
were assessed: a. The trait characterized as the categorical
MetS (c-MetS) was studied according to the NCEP defini-
tion; b. The underlying (latent) traits or clusters of MetS
(q-MetS) were evaluated by performing FA with and with-
out Varimax rotation on 11 risk factors. All data were
grouped by ethnicity and gender. Subgroups were created
by excluding T2D participants, under the assumptions
that T2D individuals may have a different pattern of glu-
cose and insulin levels. Finally, our goal was to compare
the expression of c-MetS and q-MetS in the Hypertension
Genetic Epidemiology Network (HyperGEN) study.
Results
Sample size and relationships among original risk factors
For c-MetS the sample sizes varied from 2,025 observa-
tions for fasting triglycerides (TG) to 2,300 for high den-
sity lipoprotein (HDL) cholesterol in Blacks, and from
2,171 observations for TG to 2,471 for HDL in Whites. In
the HyperGEN study, a high percentage of individuals
have body waist (WAIST) and systolic blood pressure
(SBP) / diastolic blood pressure (DBP) above the NCEP
thresholds (Figure 1). Whites tended to have greater per-
centages of participants with TG and HDL beyond the
NCEP thresholds than Blacks. The prevalence of c-MetS
was 34 and 39 percent in Blacks and Whites, respectively.
For q-MetS, the sample sizes and variables studied are
summarized in Table 1 (the statistics were similar when
T2D subjects were excluded, results not shown). After par-
ticipants with missing data for any of the 11 original vari-
ables were excluded, this resulted in a sample of 1,422
Blacks and 1,470 Whites with complete data. The samples
reduced to 1,173 Blacks and 1,322 Whites when T2D par-
ticipants were excluded.
In terms of the participants with complete data, the age at
clinic visit had a mean of 46 and a standard deviation of
13 years in Blacks, and a mean of 51 and a standard devi-
ation of 14 years in Whites. Overall, when compared to
Whites, Blacks tended to have a higher body mass index
(BMI), fasting plasma glucose (GLUC), fasting insulin
(INS), HDL, SBP, DBP, WAIST, and percent body fat
(%BF), similar low density lipoprotein (LDL) cholesterol
and waist to hip ratio (WHR), and lower TG. Kurtosis after
adjustments varied from 0.11 for WHR to 0.85 for DBP in
Blacks, and 0.17 for WHR to 1.43 for GLUC in Whites,
which demonstrates normal distributions for the traits in
study and also for the factors created by performing FA
(see Material and Methods).
Pearson correlations among the 11 adjusted and normally
distributed variables are presented in Table 2. The lower
triangle correlations correspond to all data, whereas the
upper triangle refers to the data excluding T2D partici-
pants. In both ethnicities, strong correlations were
observed among BMI, WAIST, %BF, INS, and WHR.
GLUC correlated significantly with INS (inversely,
because GLUC was inversely squared transformed). HDL
cholesterol had a significantly negative correlation withPage 2 of 9
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Interestingly, WAIST correlated higher with BMI (about
0.9) than with WHR (about 0.7) in all groups. These inter-
correlations determine the structure of the factors.
FA with no rotation identified a factor (Factor 1) that was
loaded mostly by central obesity, obesity risk factors and
INS (Table 4, see Additional file 1 ). It explained 21 per-
cent to 32 percent of the variance of the original risk fac-
tors. Three other factors, "Obesity," "Blood pressure," and
"Lipids," were identified. In Blacks, the "Obesity" factor
was primarily loaded by BMI, INS, WAIST, and %BF. In
Whites, exclusion of T2D participants led to a similar pat-
tern. However, in all data in Whites, the first factor repre-
sented a stronger mixture of central obesity, obesity and
INS, leaving the fourth factor with mainly WHR loading.
In order to distinguish the second factor from the first
one, we labeled the first as "Central obesity" factor and the
second as "Obesity" factor. In both ethnicities, blood
pressure (BP) gave rise to a separate factor. Also the "Lip-
ids" remained as a separate factor and was dominated
mainly by HDL and TG. INS was associated mostly with
the "Obesity" and "Lipids" factors.
In the case of FA with Varimax rotation, again, 4 distinct
factors explained about 60 percent of the variance in the
original variables (Table 4, see Additional file 1). We are
labeling them as "Obesity," "BP," "Lipids," and "Central
obesity". Factor loadings less than 0.1 were not listed in
Tables 3 and 4 (see Additional file 1). The first factor alone
Categorical MetS (c-MetS) in the HyperGEN StudyFigure 1
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original risk factors, while the fourth factor explained 7
percent to 9 percent of the variance. The "Obesity" factor
(Factor 1) loaded mainly BMI, WAIST, WHR, %BF, and
INS. SBP and DBP loaded separately. A distinct factor
("Lipids") loaded mainly HDL cholesterol, TG, INS and
GLUC in Blacks and HDL cholesterol, TG and INS in
Whites. The fourth factor contained a higher loading for
WHR than for WAIST. Similar factor loadings were present
in the samples when T2D participants were excluded
(Table 4, see Additional file 1).
FA with Varimax rotation was performed also by gender
(Table 3). Between genders, the factors loaded in a similar
fashion in Blacks and Whites. WHR and WAIST reflected
gender differences in their loadings in factors 1 and 4.
Discussion
The fact that MetS is more prevalent in the HyperGEN
study as compared to the average of the US adult popula-
tion [10,11], is probably due to selection bias arising from
the hypertension selection criterion applied in HyperGEN
(see Material and Methods). Although BP was an impor-
tant contributor to the categorical definition of the MetS
(c-MetS), other risk factors such as WAIST, HDL and TG
were also important. The HyperGEN Whites had a higher
prevalence of c-MetS than the Blacks. Blacks had a higher
percentage of participants with WAIST, BP, and GLUC
beyond the NCEP thresholds.
In this study, FA of 11 potential risk factors for CVD and
T2D yielded 4 latent factors, explaining about 60 percent
of the variance in the original risk factors. Using the max-
imum likelihood estimation (MLE) method in S-PLUS
(Insightful Corporation software), we found that the
model p-values were significant, suggesting that addi-
tional factors may exist. However, although additional
factors must exist to explain approximately 40 percent of
the variance in the original variables, none of the remain-
ing factors individually can explain more than about 5
percent of the variance. Therefore, we concluded that the
quantitative structure of MetS can be described in terms of
three to four factors when no rotation was performed, and
four factors with Varimax rotation. One may even argue
whether the fourth factor in the Varimax rotation is very
meaningful. We chose to retain the "Central Obesity" fac-
tor particularly because it tends to reflect the well-known
gender asymmetry (Table 3). FA without and with Var-
imax rotation can be useful in different settings. We
believe that FA without any rotation makes more sense
when investigating the pattern of risk factor clustering in
the MetS. On the other hand, gene finding studies can be
enhanced with Varimax rotation because, it is easier to
find genes each of which influences a different (uncorre-
lated) factor. Therefore, depending on the goals of a study,
rotation may or may not be used. We regard this flexibility
as strength of the FA method.
We tested the pattern of the factors between genders only
for FA with Varimax rotation. This pattern was stable
among ethnicities between genders (Table 3). WHR on
Factors 1 and 4 and WAIST on Factor 4 had statistically
different loadings in males and females.
Another characteristic of the HyperGEN study was that at
least two participants in each sibship had hypertension. A
large proportion of the hypertensive participants have
used anti-hypertensive and anti-cholesterol medications.
Table 1: Original Data Included in Factor Analysis
Blacks (N = 1422) Whites (N = 1470)
Variable Units Kurtosis Skewness Mean Std Dev Kurtosis Skewness Mean Std Dev
BMI kg/m2 0.51† 0.72 32.04‡ 7.54 0.67 0.77 28.86 5.57
GLUC mg/dl 0.68 0.70 107.37 44.06 1.43 -0.55 100.80 26.38
INS µU/ml 0.34 0.06 10.55 9.24 0.42 0.23 7.45 5.90
LDL mg/dl 0.31 0.33 118.89 36.63 0.36 0.26 116.41 31.56
HDL mg/dl 0.46 0.22 53.58 15.17 0.17 0.18 48.70 14.09
TG mg/dl 0.41 0.35 101.32 56.03 0.17 0.20 144.77 75.24
SBP mm Hg 0.46 0.68 128.45 21.78 0.44 0.62 120.50 18.33
DBP mm Hg 0.85 0.60 74.08 11.59 0.42 0.44 68.96 9.94
WAIST cm 0.51 0.64 102.05 17.78 0.74 0.71 99.22 15.48
WHR ratio 0.11 0.10 0.90 0.08 0.17 0.05 0.92 0.09
%BF % 0.44 0.17 40.00 12.06 0.33 0.57 33.41 9.29
†Kurtosis and skewness are reported after the data were transformed (where necessary) and adjusted (see Material and Methods); ‡number of 
observations, mean, and standard deviations represent measures from the final sample in factor analysisPage 4 of 9
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icated groups to see any implications of the medication
use in FA. They applied FA to 9 risk factor changes over
time, and separated data into groups of treated and
untreated for hypertension and dyslipidemia. They found
3 and 4 factors respectively in males and females, the
"BP", "Glucose," "Lipid," and "BMI, WHR, INS and TG"
factors, which were similar between treated and untreated
groups.
It is a common belief that T2D participants may have a
different expression of INS and GLUC, therefore it may
influence also the factors pattern in the MetS analysis. In
the present study, we found a consistency of the factors
before and after removing type 2 diabetics. This finding is
supported also by Hanson et al. [17] who studied two
samples of Pima Indians classified as T2D and non-T2D.
They identified consistently 4 latent factors out of 10 risk
factors in the two samples, with a relative variation only
on insulin loadings. They found that the "Insulinemia"
factor explained 30 percent of the original variance, "Body
size" 20 percent, "BP" 15 percent, and "Lipids" 14 percent.
In our study, the INS variable loaded with BMI, WAIST,
%BF, and also with lipids. INS was present mainly in 2
and sometimes in 3 factors with loadings mostly in the
"Obesity" and "Lipids" factors.
Other studies have provided similar results about the
latent traits of MetS [4,16,17]. FA studies cited here, and
other studies described by Meigs [3], have elements in
common with our study: 2 to 4 factors were identified;
BMI, INS, WHR and WAIST are major contributing risk
Table 2: Correlation Matrix of the Variables Included in Factor Analysis
Variables ** Blacks: Upper Triangle: All Data Excluding T2D
(N = 1422 / 1173) BMI INS GLUC LDL HDL TG SBP DBP WAIST WHR %BF
Lower 
Triangle:All 
Data
BMI 0.56‡ - 0.33‡ 0.15‡ - 0.22‡ 0.15‡ 0.18‡ - 0.04 0.91‡ 0.45‡ 0.78‡
INS 0.51‡ - 0.50‡ 0.16‡ - 0.37‡ 0.32‡ 0.04 - 0.08† 0.57‡ 0.44‡ 0.49‡
GLUC 
- 0.29‡ - 0.40‡ - 0.16‡ 0.25‡ - 0.26‡ - 0.06 0.03 - 0.33‡ - 0.26‡ - 0.28‡
LDL 0.13‡ 0.11‡ - 0.11‡ - 0.18‡ 0.23‡ - 0.00 - 0.05 0.14‡ 0.11† 0.17‡
HDL - 0.20‡ - 0.35‡ 0.23‡ - 0.16‡ - 0.41‡ 0.02 0.06 - 0.25‡ - 0.25‡ - 0.20‡
TG 0.17‡ 0.32‡ - 0.31‡ 0.20‡ - 0.41‡ 0.05 - 0.01 0.20‡ 0.28‡ 0.16‡
SBP 0.17‡ 0.02 - 0.07* 0.02 0.05 0.06 0.76‡ 0.16‡ 0.12† 0.06
DBP - 0.04 - 0.08† 0.04 - 0.02 0.08† - 0.00 0.74‡ - 0.03 0.03 - 0.06
WAIST 0.90‡ 0.52‡ - 0.32‡ 0.14‡ - 0.23‡ 0.22‡ 0.15‡ - 0.03 0.70‡ 0.75‡
WHR 0.44‡ 0.42‡ - 0.32‡ 0.10† - 0.25‡ 0.30‡ 0.11‡ 0.02 0.69‡ 0.407‡
%BF 0.76‡ 0.44‡ - 0.24‡ 0.16‡ - 0.18‡ 0.16‡ 0.03 - 0.06* 0.74‡ 0.37‡
Variables Whites: Upper Triangle: All Data Excluding T2D
(N = 1470 / 1322) BMI INS GLUC LDL HDL TG SBP DBP WAIST WHR %BF
Lower 
Triangle:All 
Data
BMI 0.55‡ - 0.30‡ 0.01 - 0.21‡ 0.20‡ 0.19‡ 0.07* 0.89‡ 0.46‡ 0.77‡
INS 0.52‡ - 0.30‡ - 0.01 - 0.35‡ 0.34‡ 0.22‡ 0.15‡ 0.52‡ 0.36‡ 0.45‡
GLUC - 0.32‡ - 0.31‡ - 0.08* 0.13‡ - 0.16‡ -
0.12†
- 0.09* - 0.30‡ - 0.25‡ - 0.26‡
LDL 0.02 - 0.02 - 0.05 - 0.04 0.08* 0.05 0.07 0.04 0.08* 0.07*
HDL - 0.22‡ - 0.37‡ 0.21‡ - 0.02 - 0.43‡ 0 0.01 - 0.20‡ - 0.21‡ - 0.12†
TG 0.20‡ 0.33‡ - 0.21‡ 0.06* - 0.45‡ 0.13† 0.09† 0.22‡ 0.23‡ 0.20‡
SBP 0.17‡ 0.19‡ - 0.13‡ 0.04 0.00 0.10† 0.70‡ 0.15‡ 0.13‡ 0.09†
DBP 0.03 0.09† 0.00 0.06 0.01 0.06 0.67‡ 0.06 0.09† 0.03
WAIST 0.89‡ 0.49‡ - 0.33‡ 0.04 - 0.21‡ 0.23‡ 0.14‡ 0.02* 0.70‡ 0.77‡
WHR 0.46‡ 0.35‡ - 0.25‡ 0.06 - 0.23‡ 0.25‡ 0.11† 0.07* 0.69‡ 0.44‡
%BF 0.76‡ 0.43‡ - 0.25‡ 0.08† - 0.12‡ 0.18‡ 0.11† 0.01 0.76‡ 0.43‡
*p < 0.05 † < 0.01 ‡ < 0.0001
**Variables were adjusted for age and center within ethnicity and gender (see Material and Methods)
A negative correlation between GLUC and INS is result of the inverse squared transformation of the original GLUCPage 5 of 9
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associated with more than one factor and mainly with
obesity and lipids.
Our study and several others have shown that FA is a use-
ful method for studying the underlying traits of MetS.
Nevertheless this methodology has not passed without
been criticized. Lawlor et al. [18] reviewed 22 published
studies of the MetS, all based on FA. None of the studies
had clearly identified whether they used FA for explora-
tory analysis or for hypothesis testing purposes. Such
ambiguous use was regarded by Lawlor et al [18] as a
major misuse of FA in the study of the metabolic syn-
drome. In fact exploratory FA and the hypothesis-testing
(confirmatory) FA are two distinct methods. Basically, the
two analyses use different constraints and different
approaches in the analytical software. The exploratory FA
is driven by the data (example is our study). On the other
hand, the hypothesis-testing FA is only performed with
some prior knowledge of possible loadings for different
risk factors. One applies confirmatory FA on the data to
test if the factor structure of the hypothesized model spec-
Table 3: Factors, Loadings, and Sums of Squared Loadings in All Data (Males (M) and Females (F)), and by Gender (M, F) (Varimax 
Rotation)
Factor 1 (Obesity) Sample BMI* %BF WHR WAIST INS GLUC SBP DBP LDL HDL TG SS Loadings
Blacks M+F (1422) 0.95† 0.71 0.32 0.86 0.42 -0.20 0.13 2.49
M (483) 0.92 0.71 0.65 0.95 0.46 -0.15 0.11 0.11 -0.21 0.14 2.91
F (939) 0.96 0.71 0.23 0.84 0.40 -0.22 0.14 2.43
Whites M+F (1470) 0.94 0.77 0.40 0.86 0.46 -0.26 0.14 -0.11 0.11 2.69
M (721) 0.94 0.76 0.55 0.93 0.48 -0.26 -0.13 0.16 2.99
F (749) 0.94 0.81 0.31 0.84 0.46 -0.28 0.18 -0.11 0.11 2.69
Factor 2 (BP) Sample BMI %BF WHR WAIST INS GLUC SBP DBP LDL HDL TG SS Loadings
Blacks M+F (1422) 0.99 0.76 1.58
M (483) 0.13 0.83 0.83 1.42
F (939) 0.99 0.77 1.59
Whites M+F (1470) 0.13 0.88 0.76 1.39
M (721) 0.14 0.87 0.80 1.41
F (749) 0.12 -0.14 0.98 0.65 0.11 1.45
Factor 3 (Lipids) Sample BMI %BF WHR WAIST INS GLUC SBP DBP LDL HDL TG SS Loadings
Blacks M+F (1422) 0.22 0.19 0.31 0.24 0.52 -0.43 0.27 -0.57 0.64 1.49
M (483) 0.17 0.12 0.29 0.18 0.48 -0.19 -0.72 0.65 1.37
F (939) 0.18 0.11 0.29 0.21 0.49 -0.41 0.32 -0.55 0.59 1.32
Whites M+F (1470) 0.23 0.17 0.27 0.21 0.51 -0.27 -0.68 0.64 1.41
M (721) 0.14 0.41 -0.18 -0.18 -0.75 0.61 1.20
F (749) 0.25 0.19 0.24 0.23 0.5 -0.34 0.11 0.22 -0.70 0.60 1.44
Factor 4 (Central Obesity) Sample BMI %BF WHR WAIST INS GLUC SBP DBP LDL HDL TG SS Loadings
Blacks M+F (1422) 0.90 0.40 0.15 -0.13 0.11 1.03
M (483) -0.19 0.37 0.11 0.2
F (939) 0.93 0.44 0.15 -0.16 0.11 1.13
Whites M+F (1470) 0.16 0.69 0.47 -0.10 0.76
M (721) 0.11 0.57 0.27 -0.11 0.13 0.45
F (749) 0.92 0.44 0.14 1.10
* Variables were adjusted for age and center within ethnicity and gender (see Material and Methods)
 GLUC negative loadings are result of inverse squared power transformation of the original GLUC;† Loadings ≥ 0.4 are in boldPage 6 of 9
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and the latent factors included in the model is true or not.
A detailed example of the confirmatory FA of the meta-
bolic syndrome is provided by Shen et al. [16].
If c-MetS and q-MetS are explaining the same disorder in
two different aspects in the HyperGEN study, can FA con-
tribute to MetS gene finding? MetS is recognized as a pre-
cursor for cardiovascular disease and type 2 diabetes [19].
There are several studies that have used FA for understand-
ing the complexity of the MetS. Our study brings in more
evidence that FA provides not only insights about the
latent factor traits for MetS, but it produces factor scores
for each of the MetS domains at the same time. Can factor
scores be used in genetic analysis, such as in linkage anal-
ysis? The concept of a latent factor has much (intellectual)
parallel with the concept of a latent gene. Much like a
latent gene might have pleiotropic effects on several corre-
lated phenotypes (original risk factors), several correlated
risk factors load onto a latent factor. This makes FA very
attractive from a genetic analysis point of view since,
unlike individual risk factors each of which may entail
several genes, each factor is likely to involve only a few
genes which simplify their discovery. We believe that FA is
useful for complex disease gene finding. In a near future
motivated from this analysis we plan in the HyperGEN
study to perform linkage analysis on the trait established
by c-MetS and also on factor scores created by q-MetS, for
identifying essential MetS putative genes / QTLs.
Conclusions
These analyses demonstrated that obesity and hyperten-
sion were the most important factors contributing to the
MetS in the HyperGEN Study. Three to four distinct factor
domains were identified depending on the FA rotation
applied and decisions made. Results support the hypoth-
esis that MetS is a compound phenotype, where obesity
and its relationship to lipids and insulin are clearly the
driving force of MetS. Insulin may play a connecting role
between obesity and lipid domains.
In genetic analysis, it is well known that categorical data,
especially a complex trait such as MetS, encounter reduced
power as compared to quantitative variables. Therefore,
we suggest that genetic analysis should be performed on
specific combinations of traits that belong to a factor. It is
possible that some common genes may exist in the path-
ways for the factors identified. Linkage analysis
investigating putative quantitative trait loci for MetS factor
domains can be a first step which may help discover the
underlying mechanisms, or generate new hypotheses, in
finding the causes of MetS.
Material And Methods
Data collection and MetS definition
The sample represents data from the HyperGEN network,
part of the Family Blood Pressure Program, supported by
the NHLBI as described by Williams et al. [20] and Prov-
ince et al. [21]. The ethnicity was recorded as a self-
reported demographic category. In the HyperGEN study
sibships were recruited, each with at least 2 members who
were hypertensive before age 60. Also, parents and off-
spring of some of the hypertensive sibs, as well as random
samples of unrelated Blacks and Whites, were recruited,
totaling 4,781 participants. Insulin measurements are not
available in a part of the sample and therefore the sample
size was smaller for FA. Also, participants with missing
values for any of the quantitative risk factors used in the
definition of MetS were excluded. A detailed account is
provided in the Results section.
A participant was classified as having T2D if (s)he had a
fasting plasma glucose value ≥ 126 mg/dl, or is a current
user of hypoglycemic medication or insulin that was doc-
umented at examination in the clinic, or if diabetes was
reported in the HyperGEN questionnaire. Also, an age at
diagnosis ≥ 40 years was required for T2D individuals
[22].
c-MetS according to the NCEP definition, was identified
in participants by the simultaneous presence of 3 or more
of the following conditions: WAIST > 102 cm in men, and
> 88 cm in women; TG ≥ 150 mg/dl; high density lipopro-
tein (HDL) < 40 mg/dl in men, and < 50 mg/dl in women;
systolic blood pressure (SBP) ≥ 130 mm Hg and/or diasto-
lic blood pressure (DBP) ≥ 85 mm Hg or using antihyper-
tensive medications; GLUC ≥ 110 mg/dl or on treatment
for diabetes [2].
Factor analysis was founded on 11 variables: BMI
expressed as the ratio of body weight divided by body
height squared (in kg/m2); WAIST measured at the level of
the umbilicus in cm; WHR defined as waist circumference
divided by hip circumference; GLUC in mg/dl; INS in µU/
ml (where fasting time was defined as ≥ 12 hours before
blood draw); LDL in mg/dl; HDL in mg/dl; TG in mg/dl;
Sitting SBP in mm Hg; DBP in mm Hg (SBP and DBP were
measured three times after the subject was asked to sit for
five minutes, with the mean of the second and third meas-
urements of each variable being used in the analysis);
%BF derived from the bioelectric impedance measure-
ments based on the Lukaski formula [23].
Statistical Analysis
TG and INS had skewed distributions. A relatively skewed
distribution was also present for HDL. Log transformation
brought these variables distributions to approximately
normal. GLUC and %BF were highly kurtotic. Using Box-Page 7 of 9
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squared transformation of GLUC (1/GLUC2) and the
squared transformation of %BF (%BF2) reduced the excess
kurtosis considerably. The procedure transreg in SAS (ver-
sion 9 for PC) was employed for finding power
transformations.
There were two field centers recruiting Blacks and four
field centers recruiting Whites. Accordingly, dummy (0,1)
field center variables, one for Blacks and three for Whites,
were created. All 11 risk factors were adjusted within eth-
nicity and gender for age, age2, age3, and field center
effects using stepwise regression analysis within ethnicity
and gender by employing SAS (SAS version 8.2 for Linux).
Any variables with outliers beyond ± 4 standard devia-
tions (SD) were also adjusted for heteroscedasticity of the
variance. After the adjustments for each variable, outliers
beyond ± 4 SD were eliminated. Each final adjusted vari-
able was standardized to a mean 0 and variance 1.
Prevalence of c-MetS was estimated with the FREQ proce-
dure of SAS. The multivariate method of factor analysis
was employed for reducing a group of risk factors to a sub-
set of latent factors. The primary goal of FA is to identify
the interrelationships among a set of variables. In this
study FA was used for exploratory analysis, because there
was no a priori information about the structure underlying
the variables. FA can be used also for a confirmatory anal-
ysis, when validation (or refutation) of a postulated struc-
ture is sought. In either case, FA seeks parsimony by
summarizing a large group of interrelated variables (risk
factors for a complex disease such as MetS) in terms of a
small number of latent factors, thereby reducing the
dimensionality. Theoretical statistical descriptions of FA
can be found in the literature [24-26]. FA was performed
with S-PLUS 6.0.1 software by using the factanal function,
in which the MLE was employed. FA evaluated latent fac-
tors underlying the 11 original variables.
FA was performed with and without the Varimax rotation.
"No rotation" achieves the simplest latent factor structure,
in the extreme case loading any variable in one of the fac-
tors and almost negligible loadings in the rest of the fac-
tors. That is the reason why some studies (extracting
factors with no rotation) find a concentration of the major
variables' loading on the first factor. This is also the reason
why some investigators named the first factor in their
studies as the "Metabolic syndrome" factor [3,27]. Con-
versely, when Varimax rotation is applied, the objective is
to maximize the independence of the clusters for variables
that load onto factors. This is achieved by loading in sep-
arate factors distinct combinations of the interrelated risk
factors. A loading of 0.4 or larger was considered as a sig-
nificant contribution of an original variable to a factor.
List of abbreviations used
MetS, metabolic syndrome; c-MetS, categorical MetS; q-
MetS, latent traits of MetS; FA, Factor analysis; MLE, max-
imum likelihood estimate; T2D, type 2 diabetes; CVD,
cardiovascular disease; BMI, body mass index; INS, fasting
insulin; GLUC, fasting glucose; WHR, waist to hip ratio;
SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; BP, blood pressure; TG, fasting triglycerides; LDL,
low density lipoprotein cholesterol; HDL, high density
lipoprotein cholesterol; %BF, percent body fat.
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